Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.
about
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumoursFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsImaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentSomatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation.Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumorsCorrelation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.Somatostatin analogs and radiopeptides in cancer therapy.Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy.Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomasTumour biology of gastroenteropancreatic neuroendocrine tumours.Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and ImmunohistochemistryInverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancySomatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Roles of pathologists in molecular targeted cancer therapy.The somatostatin receptor subtype 5 in neuroendocrine tumours.A systematic review of diagnostic procedures to detect midgut neuroendocrine tumors.The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.Translation of molecular pathways into clinical trials of neuroendocrine tumors.Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.(68)Ga-DOTATATE PET in juvenile angiofibroma.Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.Cross sectional and nuclear medicine imaging of pancreatic insulinomas.Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier.Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes.Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.Expression of hypothalamic neurohormones and their receptors in the human eyeThe Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes.
P2860
Q24685837-2D3FB247-C7AE-4A33-9AE0-8D728BD86909Q26822011-8C8818E6-9B2D-4F59-A029-95789AEA716CQ26862544-13604EC4-4DFF-472A-91C5-51D0883C5B78Q28083433-09AC9147-4266-48E2-A9DE-389CBD9B2B1DQ33598860-A95F94AE-35A2-4D03-8720-2F008689CD6AQ33917064-58C02FA0-4173-48E3-8B33-D71A254B6FB7Q34121454-3AC478DF-B64B-4799-896C-E8F0AB63F421Q34257556-80A16BE7-658B-48BA-ADC9-F59C3FC58FD1Q34511149-D55692A8-847B-43A0-81CB-928C5F7ACD1CQ34696158-19487148-B94F-45C3-963B-4EA865A9317DQ34972896-CADF3B29-42A5-4E1B-BCB5-7BB43CB3517FQ35010580-7A624119-2954-49F7-8C40-26F3A478302CQ35713096-B63E143A-673A-4C6A-8AB2-6C43BB5EC866Q35760798-8D164EF5-DE17-41D8-8104-98389DE83019Q35769837-708884BE-50DB-4B48-939D-B09D9A1FD7B5Q35914974-B270A7D9-F744-4BAE-9EF7-D5CD5244AD4BQ36008285-010E7164-73CF-4B3A-9E61-A0B6ED56D16DQ36090916-B544D4E7-1F50-4B75-8C6E-6660002203DBQ36413831-011BA370-5CB2-40DF-9A2C-718ED2CEA439Q37483944-C1491557-5DBC-4324-902E-1DF81E5F30C7Q37579225-6518DDB9-0414-492D-91E9-925E038CA604Q37627937-6F41740A-2ACE-4DFD-91F6-AE6BC0FC1E66Q37691450-7BC13724-2329-4B0C-84D7-400E52A616ACQ37784764-E27F78F8-E615-4D2F-A923-89E500FD3AB1Q37869391-A736D7DF-E46D-43E5-BCCE-0DB14126F206Q38003074-EDF234C1-E5C4-46B6-92BE-4EC34AE3D726Q38132768-880663F9-3DD3-409B-8422-B153C4B70803Q38175857-4B7FE66D-C8CC-4B02-9856-FF67A28F9913Q38406569-9021A3AD-A24E-4C06-B0BE-A85089C5245DQ38895856-21634D67-0435-4475-8270-9C3812986888Q38928817-F3D09D20-DDB6-426C-875D-69E689AD694DQ38957569-9A0CCF75-7B1B-4532-81D5-1A8BEBF6D15FQ39164157-3A8C4AC2-2021-448A-939A-F2348DEFE3BBQ40505318-EFC10EFC-06BC-4912-8D3C-3917802C2995Q40540183-D0129020-0D3B-431C-B9CE-A96E2A9B6ACAQ40582226-69B4003A-C66F-4E46-9361-D3BA8C279FB2Q41496806-3C4CED6E-32D8-4184-B465-F15E85C3B781Q42366509-F481BA40-36AC-4095-811E-FD62BF52D4CDQ47822235-20C9E86B-2C65-48B9-8D94-60E68362A634Q47992702-3A656746-9DB5-466D-919F-744AE43CC0D3
P2860
Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Identification of somatostatin ...... h subtype specific antibodies.
@en
Identification of somatostatin ...... h subtype specific antibodies.
@nl
type
label
Identification of somatostatin ...... h subtype specific antibodies.
@en
Identification of somatostatin ...... h subtype specific antibodies.
@nl
prefLabel
Identification of somatostatin ...... h subtype specific antibodies.
@en
Identification of somatostatin ...... h subtype specific antibodies.
@nl
P2093
P2860
P356
P1433
P1476
Identification of somatostatin ...... h subtype specific antibodies.
@en
P2093
H Kulaksiz
P2860
P356
10.1136/GUT.50.1.52
P407
P577
2002-01-01T00:00:00Z